BASEL, Switzerland, June 01, 2022 / B3C newswire / -- Celonic Group, a Swiss-German contract development and manufacturing organization (CDMO), has appointed Dr. Samanta Cimitan as the Chief Business Officer (CBO) of Celonic Group.
With more than 20 years’ experience working, teaching, and studying in Life Sciences, Samanta is an expert in the CDMO industry, holding a deep and unique combination of scientific, commercial, and operational know-how. As a member of the executive leadership team starting 01 June 2022, Samanta will be responsible for Sales, Business Development, Marketing, and Program Management.
Dr. Konstantin Matentzoglu, Chief Executive Officer of Celonic commented: “I am excited to welcome Samanta to our executive leadership team as the Chief Business Officer. She is a respected leader with an impressive track record within large global organizations in the life science industry. Her appointment will further consolidate Celonic’s aspiration towards Commercial Excellence and to continue to deliver outstanding biomanufacturing services. With her expertise, Samanta will help driving accelerated growth and long-term success for Celonic.”
Samanta joins from Lonza Group, after almost thirteen years holding several leadership positions across multiple commercial and strategy functions. Most recently, she was Vice President of Lonza Group Operations Strategy, developing and leading transformational programs across R&D, Operations and Commercial functions.
Prior to joining Lonza, Samanta was Head of Business Ventures Life Sciences for Ciba AG/ BASF with responsibility for global teams across technical development, business development, and marketing.
Samanta holds a Ph.D. in Pharmaceutical Sciences from the University of Bologna, Italy, along with a master’s degree in Industrial Chemistry.
Samanta Cimitan says: “I am delighted to join the highly skilled and collaborative team at Celonic, at such a pivotal time for the CDMO industry. I am certain of Celonic’s potential as a dynamic and forward-thinking group, committed to advancements that reduce complexity and increase biotherapeutics manufacturing effectiveness. As a united team working toward the same vision, I intend to build upon Celonic’s essence rooted in empathy, efficiency, and excellence. This solid foundation, combined with a holistic approach to science and innovation, will address unique customer challenges and develop bespoke solutions for long-term partnership along the product lifecycle. I’m excited for what we will achieve together.”
Celonic, a global CDMO (contract development & manufacturing organization) for innovative biopharmaceuticals, including cell and gene therapy products, is part of the private and independent family-owned company J.RETTENMAIER & Soehne (JRS-Group), with sites in Basel, Switzerland (headquarters) and Heidelberg, Germany. Celonic provides comprehensive development and manufacturing services for biotherapeutics including cell line development, USP and DSP development, GMP and non-GMP manufacturing of biopharmaceutical drug substances and drug products, along with cell expression platforms. With the upcoming state-of-the-art GMP manufacturing facility for gene vectors and cell therapy, Celonic is expanding its existing ATMP development and GMP manufacturing capacity in the upcoming Life Science Park Rheintal in Stein, Switzerland.
Follow @CelonicGroup on LinkedIn
Follow @AgCelonic on Twitter
Digital Marketing Lead
+41 61 56 49 150
Published by B3C newswire